These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

621 related items for PubMed ID: 16490870

  • 1. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
    Ozsahin M, Betz M, Matzinger O, Bron L, Luthi F, Pasche P, Azria D, Mirimanoff RO, Zouhair A.
    Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A, Kennedy T, Pellitteri P, Wood C, Christie D, Yumen O.
    Int J Radiat Oncol Biol Phys; 2007 Dec 01; 69(5):1361-8. PubMed ID: 17869022
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
    Bardet E, Martin L, Calais G, Tuchais C, Bourhis J, Rhein B, Feham N, Alphonsi M.
    Semin Oncol; 2002 Dec 01; 29(6 Suppl 19):57-60. PubMed ID: 12577246
    [Abstract] [Full Text] [Related]

  • 5. Accelerated postoperative radiotherapy with weekly concomitant boost in patients with locally advanced head and neck cancer.
    Zouhair A, Azria D, Pasche P, Stupp R, Chevalier J, Betz M, Mirimanoff RO, Ozsahin M.
    Radiother Oncol; 2004 Feb 01; 70(2):183-8. PubMed ID: 15028406
    [Abstract] [Full Text] [Related]

  • 6. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M, Rosenthal DI, Chalian AA, Lustig R, Hershock D, Miller L, Weinstein GS, Weber RS.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):72-7. PubMed ID: 15093901
    [Abstract] [Full Text] [Related]

  • 7. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT).
    Suntharalingam M, Jaboin J, Taylor R, Wolf J, Banglore M, Van Echo D, Ord R.
    Semin Oncol; 2004 Dec 01; 31(6 Suppl 18):2-7. PubMed ID: 15726515
    [Abstract] [Full Text] [Related]

  • 8. Feasibility and early results of accelerated radiotherapy for head and neck carcinoma in the elderly.
    Allal AS, Maire D, Becker M, Dulguerov P.
    Cancer; 2000 Feb 01; 88(3):648-52. PubMed ID: 10649260
    [Abstract] [Full Text] [Related]

  • 9. Feasibility and efficacy of accelerated weekly concomitant boost postoperative radiation therapy combined with concomitant chemotherapy in patients with locally advanced head and neck cancer.
    Pehlivan B, Luthi F, Matzinger O, Betz M, Dragusanu D, Bulling S, Bron L, Pasche P, Seelentag W, Mirimanoff RO, Zouhair A, Ozsahin M.
    Ann Surg Oncol; 2009 May 01; 16(5):1337-43. PubMed ID: 19280263
    [Abstract] [Full Text] [Related]

  • 10. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI, Chambers MS, Weber RS, Eisbruch A.
    Semin Oncol; 2004 Dec 01; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [Abstract] [Full Text] [Related]

  • 11. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB.
    Cancer; 2009 Oct 01; 115(19):4514-23. PubMed ID: 19634161
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
    Koukourakis MI, Yannakakis D.
    Anticancer Res; 2001 Oct 01; 21(4B):2973-8. PubMed ID: 11712796
    [Abstract] [Full Text] [Related]

  • 14. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, de Vries A.
    Int J Radiat Oncol Biol Phys; 2006 Mar 01; 64(3):684-91. PubMed ID: 16243440
    [Abstract] [Full Text] [Related]

  • 15. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
    Jellema AP, Slotman BJ, Muller MJ, Leemans CR, Smeele LE, Hoekman K, Aaronson NK, Langendijk JA.
    Cancer; 2006 Aug 01; 107(3):544-53. PubMed ID: 16804929
    [Abstract] [Full Text] [Related]

  • 16. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
    Altmann S, Hoffmanns H.
    Strahlenther Onkol; 1999 Nov 01; 175 Suppl 4():30-3. PubMed ID: 10584138
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience.
    Allal AS, Taussky D, Mach N, Becker M, Bieri S, Dulguerov P.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1431-6. PubMed ID: 15050320
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection?
    Vacha P, Fehlauer F, Mahlmann B, Marx M, Hinke A, Sommer K, Richter E, Feyerabend T.
    Strahlenther Onkol; 2003 Jun 01; 179(6):385-9. PubMed ID: 12789464
    [Abstract] [Full Text] [Related]

  • 20. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients.
    Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC.
    Int J Radiat Oncol Biol Phys; 2009 Mar 01; 73(3):779-88. PubMed ID: 18707819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.